The Food and Drug Administration has cleared a new treatment for people with advanced melanoma who had run out of standard options. On August 6, STAT reported that the agency granted accelerated approval to Tudriqev, an engineered virus injected directly into tumors and given alongside the immunotherapy nivolumab, for adults with unresectable advanced cutaneous melanoma whose disease progressed after anti-PD-1 therapy [1].
The drug, made by Replimune and known through its trials as RP1 (vusolimogene oderparepvec-wtpg), is an oncolytic virus. Doctors inject it into a tumor, where it is designed to kill cancer cells and prime the immune system to recognize the disease; pairing it with nivolumab is meant to widen that immune response. For patients whose cancer keeps advancing after anti-PD-1 drugs, the list of things left to try has been short, which is the group this approval is written for [1].
The path here was not smooth, and the record says so. Tudriqev reached the market on Replimune's third submission, after the FDA had issued two prior complete response letters turning the drug away [1]. On July 30, 2026, an agency advisory panel voted 10 to 3 to recommend approval, and it did so over objections from the FDA's own reviewers. In STAT's account, "Even though FDA staff expressed concerns about the design and conduct of Replimune's key trial, advisers ultimately believed there was a large enough signal of efficacy and that patients are in urgent need of new treatments" [1].
The price sets a hard limit on who this reaches. STAT reports a list price of $450,000 per course before rebates [1]. A number that size will move through insurers and negotiated discounts before most patients see a bill, but it also decides, in practice, who gets the drug and who is told it is not covered. A new option that a patient cannot afford is not the same as an option.
There is also a question the approval does not yet answer: whether Tudriqev helps people live longer. This is an accelerated approval, granted on a surrogate signal rather than a survival result. Replimune's confirmatory Phase 3 trial, enrolling roughly 400 patients, is not expected to report overall-survival data until 2030 [1]. Until then, the clearance is a bet that the early efficacy signal holds up.
One housekeeping note for the record: STAT dated the approval August 6. A separate trade report, from MedCity News, placed the announcement on August 7, after the market close. The two accounts describe the same clearance, and the date discrepancy is worth resolving at review.
What is left is a modest, honest win. Patients with advanced melanoma who had exhausted the standard playbook now have something new to try. It is expensive, it cleared on the third attempt over regulators' own reservations, and the proof that it extends lives is still four years out. For someone facing this diagnosis with no options left, a new one on the table still counts, so long as everyone reading knows exactly what it is and is not.
